Brokerages Set Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Target Price at $4.50

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) has earned an average rating of “Hold” from the six brokerages that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $4.50.

Several equities research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Milestone Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, November 23rd. Wells Fargo & Company initiated coverage on shares of Milestone Pharmaceuticals in a research note on Thursday, September 11th. They issued an “overweight” rating and a $4.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a report on Monday, November 24th.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Millennium Management LLC bought a new stake in Milestone Pharmaceuticals during the 3rd quarter valued at about $803,000. Boxer Capital Management LLC bought a new stake in shares of Milestone Pharmaceuticals during the third quarter valued at approximately $1,333,000. Bank of America Corp DE boosted its holdings in shares of Milestone Pharmaceuticals by 200,550.0% in the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock valued at $32,000 after purchasing an additional 16,044 shares during the period. Orbimed Advisors LLC purchased a new position in Milestone Pharmaceuticals during the 3rd quarter worth $6,444,000. Finally, Two Sigma Investments LP purchased a new position in Milestone Pharmaceuticals in the third quarter valued at about $1,333,000. 86.18% of the stock is currently owned by institutional investors.

Milestone Pharmaceuticals Price Performance

NASDAQ:MIST opened at $2.67 on Tuesday. The firm has a market capitalization of $226.98 million, a price-to-earnings ratio of -3.25 and a beta of 0.54. The company has a debt-to-equity ratio of 2.74, a current ratio of 8.24 and a quick ratio of 8.24. The business has a 50 day simple moving average of $2.05 and a 200-day simple moving average of $1.82. Milestone Pharmaceuticals has a 1 year low of $0.63 and a 1 year high of $2.77.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.05. Equities analysts forecast that Milestone Pharmaceuticals will post -0.62 EPS for the current year.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.